STOCK TITAN

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis (OCS) reported notifications of transactions by persons discharging managerial responsibilities.

(Neutral)
(Very Positive)
Tags

Oculis (OCS) reported notifications of transactions by persons discharging managerial responsibilities. These relate to vesting and settlement of RSUs previously granted to directors, annual equity incentive awards to directors, and a one-time equity grant to a new director upon his election to the board.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus May 18 session
-7.33% close to close Open Argus
Details

News Market Reaction – OCS

In the May 18 session, OCS declined 7.33%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.3% in the session following this news. A negative reaction despite the routine na...
Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite the routine nature of director RSU vesting and equity awards would fit a pattern where some positive or neutral updates coincided with selling, such as the -6.86% move after Q1 2026 results. With shares still above the 200-day MA of 22.69, pullbacks have previously occurred within a longer-term uptrend. Prior dilutive financings and warrant-related overhangs could also influence how the market interprets governance disclosures.

Key Figures

Registered resale shares: 494,259 shares Currently exercisable warrant: 59,310 shares Potential cash proceeds: $6,877,246.59 +5 more
Registered resale shares
494,259 shares
Form F-3 resale registration
Currently exercisable warrant
59,310 shares
Portion of warrant currently exercisable
Potential cash proceeds
$6,877,246.59
If warrant fully exercised for maximum shares
Financing shares
5,432,098 shares
Equity financings announced October 31, 2025
Gross proceeds
$110.0 million
Equity financings announced October 31, 2025
Offering price
$20.25 per share
Underwritten and registered direct offerings
Shares outstanding pre-offer
52,374,811 shares
As of September 30, 2025
Shares outstanding post-offer
57,806,909 shares
Expected after offerings and direct sale

Historical Context

4 past events · Latest: May 11
4 events
  1. May 11

    Q1 earnings update

    24h Move
    -6.9%

    Reported Q1 results, strong cash runway, and late-stage pipeline timelines.

  2. May 07

    Regulatory SPA news

    24h Move
    +5.1%

    FDA Special Protocol Assessment for PIONEER-1 Phase 3 Privosegtor trial.

  3. May 05

    Clinical conference data

    24h Move
    -1.8%

    Presented DME AWARE Delphi findings and reiterated June 2026 DIAMOND data.

  4. Apr 21

    AGM invitation

    24h Move
    +0.0%

    Published notice and logistics for the 2026 Annual General Meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rsus
1 terms
rsus financial
"the vesting and settlement of RSUs previously granted to directors of the Company"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to directors of the Company, and the one-time equity incentive award granted to a new director upon his election to the board of directors of the Company.

Attachments


FAQ

What transactions did Oculis (OCS) report on May 15, 2026?

Oculis reported notifications of transactions involving directors’ restricted stock units and equity awards. According to Oculis, these cover RSU vesting and settlement, annual director equity incentives, and a one-time equity award for a newly elected board member.

Which Oculis (OCS) directors had RSU vesting transactions on May 13, 2026?

According to Oculis, RSU vesting notifications were filed for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani and Robert Warner. These transactions reflect the vesting and settlement of previously granted restricted stock units to these board members.

What equity incentive awards did Oculis (OCS) directors receive in 2026?

Oculis filed notifications for annual equity incentive awards granted to several directors in 2026. According to Oculis, these annual grants form part of the board’s compensation structure and are documented in individual manager transaction notifications for each named director.

Did Oculis (OCS) grant equity to a new director in 2026?

Yes. Oculis reported a one-time equity incentive award for new director G. Perry. According to Oculis, this award was granted upon his election to the board and is disclosed in a dedicated manager transaction notification.

Why does Oculis (OCS) publish notifications of managers’ transactions?

Oculis publishes managers’ transaction notifications to disclose equity dealings by directors and similar insiders. According to Oculis, the reported 2026 items include RSU vesting, annual equity awards and a new director grant, supporting transparency around board-related share incentives.

Keep reading